Image source: Shutterstock
Highlights
- Monash IVF disclosed an embryo transfer error at its Clayton laboratory on 5 June 2025.
- The company has initiated an internal investigation and expanded an existing independent review.
- Monash IVF implemented interim verification safeguards and notified relevant regulators and insurers.
Monash IVF Group Limited (ASX:MVF) is an ASX-listed healthcare company based in Australia, providing assisted reproductive services across clinics in Australia and Southeast Asia. The group offers a range of fertility, genetic, and diagnostic services to individuals and couples seeking fertility treatment.
The company has disclosed that an incident occurred at its Clayton laboratory on 5 June 2025, involving the incorrect transfer of a patient’s own embryo, contrary to the intended treatment plan. According to the company, the plan had designated the use of an embryo from the patient’s partner, making this a procedural error within the fertility treatment process.
The company has formally apologised to the affected couple and stated that it is providing them with ongoing support. Monash IVF has commenced an internal investigation to determine how the incident occurred and how similar events can be prevented in the future. Additionally, the scope of an ongoing independent review being conducted by Fiona McLeod AO SC has been expanded to include the Clayton incident. This review was initially commissioned in response to a separate incident at the company’s Brisbane clinic earlier in the year.
While the company emphasised that the two events are unrelated and occurred several years apart, it acknowledged the need to reinforce verification protocols. As part of its immediate response, Monash IVF announced the implementation of interim measures that include enhanced verification steps and patient confirmation procedures. These measures are designed to supplement the existing electronic witness systems currently being deployed across its facilities.
Monash IVF noted that, despite its use of automated verification systems, there are still circumstances in which manual witnessing is required, which can introduce the potential for error. The company stated that the additional interim procedures would remain in place while further reviews are conducted to evaluate longer-term changes.
The incident has been reported to relevant authorities, including the Reproductive Technology Accreditation Committee and the Victorian Health Regulator. Monash IVF has also notified its insurers and anticipates that the incident falls within the scope of its insurance coverage.
The company confirmed that its previously issued financial guidance, last updated on 20 May 2025, remains unchanged as of now. MVF shares were trading 24.83% lower at AUD 0.56 per share as of 10 June 2025.






Please wait processing your request...